Deniz Tural

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 11

Top Topics

Metastatic Renal Cell Carcinoma

Prognostic Factors

Ejection Fraction

Top Venues

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Future oncology (London, England)

International journal of clinical oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Rumeysa Çolak, Gökmen Umut Erdem, Caner Kapar, İlkay Gültürk, Faruk Aksu, Gülçin Şahingöz Erdal, Mesut Yılmaz, Deniz Tural
Change in the neutrophil-lymphocyte ratio may predict early recurrence in operated bladder cancer. Asia-Pacific journal of clinical oncology (2024)
Mahmut Emre Yildirim, Nuri Karadurmuş, İlker Nihat Ökten, Hacı Mehmet Türk, Zuhat Urakci, Çağatay Arslan, Sinemis Çelik, Faysal Dane, Mehmet Ali Nahit Şendur, Cemil Bilir, Bülent Karabulut, Irfan Cicin, Erdem Cubukcu, Mustafa Karaca, Melike Ozcelik, Mustafa Yıldırım, Eda Tanrikulu, Ahmet Alacacioglu, Özgür Açıkgöz, Başak Öven, Çağlayan Geredeli, Timucin Çil, Hakan Harputluoğlu, Umut Kefeli, Oktay Bozkurt, Deniz Tural, Abdullah Sakin, Şuayip Yalçın, Mahmut Gumus
Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wild-type patients treated with biologics second-line mCRC. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2024)
Mutlu Hizal, Burak Bilgin, Nail Paksoy, Saadettin Kılıçkap, Muhammed Mustafa Atcı, Seda Kahraman, Merve Keskinkılıç, İrem Bilgetekin, Murat Ayhan, Deniz Tural, Önder Eren, Fatma Nihan Akkoç Mustafayev, Şebnem Yaman, Ali Murat Tatlı, Ertuğrul Bayram, Yasin Kutlu, İsmail Ertürk, Erkan Özcan, Ahmet Gülmez, Mustafa Korkmaz, Baran Akagündüz, Dilek Erdem, Tuğba Akın Telli, Asude Aksoy, Necdet Üskent, Yakup İriağaç, Naziyet Köse Baytemür, Dinçer Aydın, Teoman Şakalar, Hacı Arak, Fatih Selçukbiricik, Yakup Ergün, Taner Korkmaz, Naziye Ak, Çağlar Ünal, Nadiye Akdeniz, Mehmet Alpaslan Özgün, Berna Öksüzoğlu, Bülent Yalçın, İlhan Öztop, Efnan Algın, Abdullah Sakin, Adnan Aydıner, Perran Fulden Yumuk, Mehmet Ali Nahit Şendur
Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study. Future oncology (London, England) 18 (23) (2022)
Seher Yildiz Tacar, Mesut Yilmaz, Buge Oz, Deniz Tural
Crizotinib for c-MET-amplified advanced NSCLC: a single-center experience. Tumori (2021)
Nail Paksoy, Selcuk Erdem, Mert Karaca, Naziye Ak, Metin Pehlivan, Inci K Yirgin, Yasemin Ozluk, Feza Ekiz, Deniz Tural, Meltem Ekenel, Faruk Ozcan, Mert Basaran
Multidrug refractory aggressive metastatic TFE3 (+) renal cell carcinoma: A case report. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 28 (1) (2021)
Ilkay Gulturk, Mesut Yilmaz, Aykut Ozmen, Seher Yildiz Tacar, Gülçin Sahingoz Erdal, Deniz Tural
Ribociclib induced acute kidney injury: A case report. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2021)
Deniz Tural, Fatih Selçukbiricik, Ömer Fatih Ölmez, Ahmet Taner Sümbül, Mustafa Erman, Hasan Şenol Coşkun, Mehmet Artaç, Saadettin Kılıçkap
Response to first-line chemotherapy regimen is associated with efficacy of ımmune checkpoint blockade therapies in patients with metastatic urothelial carcinoma. International journal of clinical oncology (2021)
Emre Yekedüz, İsmail Ertürk, Deniz Tural, Nuri Karadurmus, Serdar Karakaya, Mutlu Hizal, Rukiye Arıkan, Çağatay Arslan, Hakan Taban, Ahmet Küçükarda, Nihan Şentürk Öztaş, Ozlem Nuray Sever, Gokhan Ucar, Orçun Can, Mehmet Ali Nahit Şendur, Umut Demirci, Saadettin Kılıçkap, Irfan Cicin, Ömür Berna Çakmak Öksüzoğlu, Mustafa Özgüroğlu, Yuksel Urun
Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database. Future oncology (London, England) 17 (35) (2021)
Deniz Tural, Ömer Fatih Ölmez, Ahmet Taner Sümbül, Nail Özhan, Burcu Çakar, Osman Köstek, Meltem Ekenel, Mustafa Erman, Hasan Şenol Coşkun, Fatih Selçukbiricik, Özge Keskin, Fatma Paksoy Türköz, Kerem Oruç, Selami Bayram, İrem Bilgetekin, Birol Yıldız, Mehmet Ali Nahit Şendur, Nail Paksoy, Ahmet Dirican, Dilek Erdem, Meltem Selam, Özgür Tanrıverdi, Semra Paydaş, Zuhat Urakçı, Elif Atağ, Sabri Güncan, Yüksel Ürün, Ali Alkan, Ali Osman Kaya, Deniz Tataroğlu Özyükseler, Halil Taşkaynatan, Mustafa Yıldırım, Müge Sönmez, Tuğba Başoğlu, Şeyda Gündüz, Saadettin Kılıçkap, Mehmet Artaç
Prognostic factors in patients with metastatic urothelial carcinoma who have treated with Atezolizumab. International journal of clinical oncology 26 (8) (2021)
Osman Sütçüoğlu, Ayşegül İlhan, Seher Yildiz Tacar, Deniz Can Guven, Gokhan Ucar, Nuri Karadurmus, Fatih Yildiz, Emrah Eraslan, Doğan Uncu, Deniz Tural, Aytuğ Üner, Nazan Günel, Nuriye Ozdemir, Saadettin Kılıçkap, Ömür Berna Çakmak Öksüzoğlu, Ahmet Özet, Ozan Yazıcı
Thirty-day mortality rates after immunotherapy initiation. Immunotherapy 13 (17) (2021)
Ozgecan Dulgar, Deniz Tataroğlu Özyükseler, Mustafa Başak, Seval Ay, Deniz Tural, Mahmut Emre Yıldırım, Mahmut Gümüş
Is the duration of castration resistance predictive for sequential treatment responses in the metastatic castration-resistant prostate cancer setting? Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 27 (6) (2020)